MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
Saizen in Intra-uterine Growth Retardation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2013-09-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 91
- Registration Number
- NCT01400698
Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 402
- Registration Number
- NCT01396395
- Locations
- 🇨🇳
For Locations in, Beijing, China
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
- First Posted Date
- 2011-07-07
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT01388790
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain
Completed
- Conditions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 300
- Registration Number
- NCT01376921
- Locations
- 🇪🇸
For Recruiting Locations in Spain, Please Contact The Merck KGaA Communication Center, Spain
Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 353
- Registration Number
- NCT01364298
- Locations
- 🇲🇽
Research Site, Mexico City, Mexico
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece
Completed
- Conditions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 180
- Registration Number
- NCT01363674
- Locations
- 🇬🇷
For Recruiting Locations in Greece,, Please Contact The Merck KGaA Communication Center, Greece
EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2011-05-26
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 13
- Registration Number
- NCT01360827
- Locations
- 🇫🇷
Clinical Research Unit and Pharmacology Lab EA 3035 Institut Claudius Regaud, Toulouse, France
Glucophage XR® Observational Study
Terminated
- Conditions
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 518
- Registration Number
- NCT01336673
- Locations
- 🇹🇭
Faculty of Medicine Vajira Hospital, Bangkok, Thailand
A Study of EMD525797 in Solid Tumor Patients in Japan
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 27
- Registration Number
- NCT01327313
- Locations
- 🇯🇵
For Recruiting, Locations in, Japan
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Australia
Completed
- Conditions
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 33
- Registration Number
- NCT01309555
- Locations
- 🇦🇺
For Recruiting Locations in Australia, Please Contact The Merck KGaA Communication Center, Australia
© Copyright 2024. All Rights Reserved by MedPath